Press Releases Items Per Page 102550 Year None2021202020192018201720162015201420132012201120102007 06.03.21 Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference 05.13.21 Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit 05.11.21 Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update 05.04.21 Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 04.20.21 Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias 04.15.21 Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias 04.08.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis 03.31.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease 03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update 03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 02.24.21 Syndax Announces Participation at Two Upcoming Investor Conferences 12.18.20 Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
05.11.21 Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update
05.04.21 Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
04.20.21 Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias
04.15.21 Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias
04.08.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis
03.31.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease
03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update
03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021
